Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC

[1]  L. Thiberville,et al.  Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab , 2022, Annals of Nuclear Medicine.

[2]  C. Mesquita,et al.  Metabolic Volume Measurements in Multiple Myeloma , 2021, Metabolites.

[3]  E. Lopci.  Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer , 2021, Journal of clinical medicine.

[4]  V. Ambrosini,et al.  Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. , 2021, European journal of cancer.

[5]  L. Guerra,et al.  Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience , 2021, Cancers.

[6]  B. Neyns,et al.  The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression. , 2021, Clinical lung cancer.

[7]  S. Rossi,et al.  Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1 , 2020, Frontiers in Oncology.

[8]  Jingyun Shi,et al.  Relationship between SP142 PD-L1 Expression and 18F-FDG Uptake in Non-Small-Cell Lung Cancer , 2020, Contrast media & molecular imaging.

[9]  J. Darcourt,et al.  Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study , 2020, Journal for ImmunoTherapy of Cancer.

[10]  M. Filetti,et al.  Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% , 2020, Cancer Immunology, Immunotherapy.

[11]  Y. Huang,et al.  PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer , 2020, EJNMMI Research.

[12]  S. Novello,et al.  18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival , 2020, Cancers.

[13]  Yingying Zhang,et al.  18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer , 2020, Annals of Nuclear Medicine.

[14]  Ning Li,et al.  The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  S. Rossi,et al.  18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art , 2019, Current radiopharmaceuticals.

[16]  J. Darcourt,et al.  18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Y. Oda,et al.  18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer , 2019, Scientific Reports.

[18]  Wengui Xu,et al.  New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  A. Russo,et al.  Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) , 2019, Advances in Therapy.

[20]  John O. Prior,et al.  18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  M. Soussan,et al.  Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST , 2019, EJNMMI Research.

[22]  Xiaoping Zhou,et al.  Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  A. Russo,et al.  Monoclonal antibodies for the treatment of non-hematological tumors: a safety review , 2018, Expert opinion on drug safety.

[24]  J. Humm,et al.  18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma , 2018, The Journal of Nuclear Medicine.

[25]  F. Grizzi,et al.  Is it time to change our vision of tumor metabolism prior to immunotherapy? , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Asfar S Azmi,et al.  Rho GTPase effectors and NAD metabolism in cancer immune suppression , 2018, Expert opinion on therapeutic targets.

[27]  E. Smit,et al.  PD-L1 IHC in NSCLC with a global and methodological perspective. , 2017, Lung cancer.

[28]  S. Baba,et al.  Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on 18F‐fluorodeoxyglucose positron emission tomography/computed tomography , 2017, Cancer medicine.

[29]  Greg M. Delgoffe,et al.  Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity , 2016, Vaccines.

[30]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[31]  A. Zimna,et al.  Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies , 2015, BioMed research international.

[32]  Kyoungjune Pak,et al.  Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[34]  T. Nakajima,et al.  Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. , 2014, Lung cancer.

[35]  Anand K. Devaiah,et al.  Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy , 2012, Annals of Nuclear Medicine.

[36]  T. Nakajima,et al.  Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. , 2012, European journal of cancer.

[37]  G. Semenza.  HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.

[38]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[39]  J. Fowler,et al.  Initial and subsequent approach for the synthesis of 18FDG. , 2002, Seminars in nuclear medicine.